SCHEMBL10084006

SCHEMBL10084006

Oc1c(Cl)cc(-c2ccc(Cl)c(Cl)c2)c(Cl)c1Cl

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 8/20 0.68
CYP1B1 Q16678 1/20 0.48
HSD17B10 Q99714 2/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
TTR P02766 1/20 0.44
PIK3CA P42336 2/20 0.42
PIK3CD O00329 1/20 0.42
GYS1 P13807 1/20 0.42
PIK3CB P42338 1/20 0.42
PIK3CG P48736 1/20 0.42
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
DHFR P00374 1/20 0.39
PTGER1 P34995 1/20 0.38
PTGER3 P43115 1/20 0.38
PTGER2 P43116 1/20 0.38
KMO O15229 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29497479 1.00 AHR (0.68) AHRCYP1B1HSD17B10HPGDTSHR
SCHEMBL5487549 0.82 HSD17B10 (0.67) AHRCYP1B1HSD17B10HPGDTSHR
SCHEMBL2279549 0.81 AHR (1.00) AHRCYP1B1MEN1HTTKMT2A
SCHEMBL29389344 0.81 AHR (1.00) AHRCYP1B1MEN1HTTKMT2A
SCHEMBL5948553 0.78 HSD17B10 (0.65) AHRHSD17B10HPGDTSHRMAPK1
SCHEMBL11714793 0.78 HPGD (0.48) AHRHSD17B10HPGDTSHRMAPK1
SCHEMBL8773713 0.76 AHR (0.70) AHRCYP1B1HSD17B10TSHRTTR
SCHEMBL15478245 0.75 HSD17B10 (0.56) AHRHSD17B10HPGDTSHRMAPK1
SCHEMBL5949069 0.75 HSD17B10 (0.50) AHRHSD17B10HPGDTSHRMAPK1
SCHEMBL29386527 0.74 HSD17B10 (0.61) AHRHSD17B10HPGDTSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653119-B2 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE (US) 2014-02-18 US disclosed
US-8168663-B2 Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof THE SCRIPPS RESEARCH INSTITUTE (US) 2012-05-01 US disclosed
US-20100120919-A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120919-A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES TTR, TTPA, PRNP AHR 4301/4885CYP1B1 4049/4885HSD17B10 1358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.